Entera Bio Ltd Dossier - Source-backed chat

Entera Bio Ltd

ENTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.27

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.89Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $500.4M

Enterprise Value $489.1M

Shares Outstanding 173.1M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Entera Bio Ltd. is a clinical-stage biopharmaceutical pioneer leveraging its proprietary N-Tab® oral peptide delivery platform to transform injectable-only biologics into convenient daily tablets. The company's lead asset, EB613 (oral teriparatide), is poised to enter a streamlined Phase 3 trial for postmenopausal osteoporosis in late 2026, benefiting from a landmark FDA alignment that qualifies Bone Mineral Density (BMD) as a primary surrogate endpoint. This regulatory pathway significantly reduces trial size (750 patients) and accelerates potential commercialization by up to a year. Furthermore, Entera's expanded 50/50 partnership with OPKO Health fully funds and accelerates its second high-potential asset, EB612 (oral long-acting PTH for hypoparathyroidism), toward an IND filing in late 2026. Backed by a recent $10 million private placement led by BVF Partners, Entera possesses a solid cash runway into Q1 2027, making it a highly attractive, asymmetric biotech play with major near-term clinical catalysts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$9.00

High · most bullish analyst$9.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5020%

The FDA requests additional preclinical or clinical bridging data for the single-tablet formulation of EB613, delaying the Phase 3 trial initiation into 2027. Delays in IND-enabling studies for EB612 push the IND filing past late 2026. With a cash runway extending only into Q1 2027, the company is forced to execute a highly dilutive equity raise at depressed share prices, severely impacting shareholder value.

Base CaseCentral scenario

$9.0050%

Matches the consensus mean

Entera successfully initiates the EB613 Phase 3 trial in late 2026 following standard FDA feedback. The EB612 IND is filed on schedule in late 2026, and Phase 1 trials begin in early 2027, funded by the existing cash balance and OPKO partnership. The company secures additional dilutive or non-dilutive financing in early 2027 to extend its runway through the Phase 3 trial, with the stock steadily re-rating toward consensus analyst targets as clinical milestones are met.

Bull CaseUpside scenario

$9.0030%

The FDA rapidly approves the streamlined Phase 3 protocol for EB613, leading to swift patient enrollment and positive topline results by 2028. Concurrently, the EB612 IND is cleared, and Phase 1 clinical data demonstrates superior bioavailability and safety, triggering a lucrative global co-development or licensing deal with a major pharmaceutical partner. The N-Tab® platform is validated across multiple metabolic indications (including EB618 for obesity), driving substantial non-dilutive upfront payments and pushing the stock toward the high-end analyst target.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary N-Tab® platform successfully delivers oral peptides with robust bioavailability and low variability, addressing a massive unmet need in patient compliance.
Streamlined Phase 3 regulatory pathway for EB613 utilizes BMD as a primary surrogate endpoint, reducing trial size to 750 patients and accelerating timeline to topline results.
Strong strategic partnership with OPKO Health on a 50/50 cost-sharing basis for EB612 and EB618, minimizing Entera's near-term R&D cash burn.
Recent $10 million private placement led by specialist biotech investor BVF Partners extends cash runway into Q1 2027, covering key pre-Phase 3 preparation activities.

Key Investment Risks

Clinical-stage risk: Lead assets EB613 and EB612 must still prove safety and efficacy in large-scale human trials.
Financing risk: Current cash reserves of $20.4 million only fund operations into Q1 2027, requiring additional capital before Phase 3 completion.
Regulatory risk: Any unexpected FDA demands regarding the single-tablet bridging data or Phase 3 protocol could delay clinical timelines.

Thesis Invalidation Triggers

FDA rejection or significant delay of the streamlined Phase 3 protocol for EB613.
Failure to file the EB612 IND application by late 2026.
Inability to secure additional financing or strategic partnerships before the cash runway expires in Q1 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.